The use of a long-acting somatostatin analogue (octreotide) for prophylaxis of acute pancreatitis after endoscopic sphincterotomy

What Was Tested

The paper reports a study of Octreotide in the context of pancreatitis (after the acute phase), published as a randomized controlled trial.

Acute pancreatitis is a serious complication of endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic sphincterotomy (EST).

Who Took Part

According to the abstract, 151 patients were involved.

The age groups tagged for this paper are middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Octreotide and who got the comparison, which limits bias.

Blinding on both sides kept the patients and researchers unaware of who received Octreotide.

Some patients received a placebo instead of Octreotide, giving a reference point.

What Was Measured

Topics PubMed links to this paper include Acute Disease, Amylases, Cholangiopancreatography, Endoscopic Retrograde, Gallstones, Octreotide, Pancreatitis and Sphincterotomy, Endoscopic.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Octreotide in 151 patients in people with pancreatitis (after the acute phase).

The publication is from 1994 (Endoscopy), a journal based in Germany.

More context: the Octreotide compound page, Pancreatitis (after the acute phase) research.